Second Lancet publication of the TRIANGLE trial

The most recent results of the European, investigator-initiated, three-arm TRIANGLE trial confirm a markedly improved overall survival time of patients under 66 years of age with the rare mantle cell lymphoma. The newly established standard of care combines an oral drug with an immunochemotherapy and omits the previously standard, toxic autologous stem cell transplantation. Through sophisticated biometrical planning, trial monitoring, and statistical analysis, Prof. Dr. Eva Hoster and her PhD student Linmiao Jiang from the Chair of Medical Biometry at the IBE contributed substantially to the international success of the TRIANGLE trial.

Links to the publications:

Martin Dreyling, Jeanette Doorduijn, Eva Giné, Mats Jerkeman, Jan Walewski, Martin Hutchings, Ulrich Mey, Jon Riise, Marek Trneny, Vibeke K J Vergote, Ofer Shpilberg, Maria Gomes da Silva, Sirpa Leppä, Linmiao Jiang, Stephan Stilgenbauer, Andrea Kerkhoff, Ron D Jachimowicz, Georg Heß, Tom van Meerten, Stefan Wirths, Peter Herhaus, Urban Novak, Judith Dierlamm, Mathias Hänel, Christine Hanoun, Kristina Sonnevi, Carlo Visco, Daniela Donnarumma, Andrés J M Ferreri, Caterina Patti, Piero Maria Stefani, Christiane Pott, Wolfram Klapper, Christian Schmidt, Michael Unterhalt, Tobias Tix, Marco Ladetto*, Eva Hoster*, on behalf of the European Mantle Cell Lymphoma Network: “Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18–65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network”; Lancet 2026; 407: 1953–67, DOI: 10.1016/S0140-6736(26)00362-4

Martin Dreyling, Jeanette Doorduijn, Eva Giné, Mats Jerkeman, Jan Walewski, Martin Hutchings, Ulrich Mey, Jon Riise, Marek Trneny, Vibeke Vergote, Ofer Shpilberg, Maria Gomes da Silva, Sirpa Leppä, Linmiao Jiang, Stephan Stilgenbauer, Andrea Kerkhoff, Ron D Jachimowicz, Melania Celli, Georg Hess, Luca Arcaini, Carlo Visco, Tom van Meerten, Stefan Wirths, Pier Luigi Zinzani, Urban Novak, Peter Herhaus, Fabio Benedetti, Kristina Sonnevi, Christine Hanoun, Matthias Hänel, Judith Dierlamm, Christiane Pott, Wolfram Klapper, Döndü Gözel, Christian Schmidt, Michael Unterhalt, Marco Ladetto*, Eva Hoster*: “Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network”; Lancet 2024; 403: 2293–306, DOI: 10.1016/S0140-6736(24)00184-3